tirzepatide vision Researchers Find Small Increased Risk of Sudden Loss Associated With GLP-1 Medications Could Ozempic and Wegovy Be

As an obesity medicine physician scientist who regularly cares for patients with complex inflammatory conditions, this study reinforces what many of us have suspected clinically that the benefits of GLP-1 receptor agonists extend well beyond blood sugar control and weight loss and may fundamentally alter the disease trajectory for some of our highest-risk patients. Stanford, who was not involved in this research, is an obesity medicine physician scientist, educator and policy maker at Massachusetts General Hospital and Harvard Medical School, both in Boston

Archived from the original on December 15, 2022

Patients often ask whether BPC-157 affects hormones, fertility, or testosterone levels

Sleep-disordered breathing and lung function abnormalities in adults with congenital heart disease